Multidisciplinary perspectives in <i>Demodex</i> blepharitis: A new view of treatment from clinical, payer, and patient perspectives

2024-10-1

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer

2024-9-11

Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan

2024-9-11

Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States

2024-9-9

Nonalcoholic steatohepatitis/metabolic dysfunction–associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective

2024-9-1

Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes

2024-9-1

Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs

2024-9-1

Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review

2024-9-1

Budget impact models for lung cancer interventions: A systematic literature review

2024-9-1

Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment

2024-9-1

Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer

2024-9-1

US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance

2024-9-1

Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder

2024-9-1

Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis

2024-9-1

Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder

2024-9-1

Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: a microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid

2024-8-7

Economic burden of recurrent hyperkalemia in patients with chronic kidney disease

2024-8-5

How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes

2024-8-1

Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018

2024-8-1

Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study

2024-8-1

Understanding racial disparities in health care expenditures for cervical cancer

2024-8-1

A primer on copay accumulators, copay maximizers, and alternative funding programs

2024-8-1

Evolving oncology care management trends in the United States: A survey among health care decision makers

2024-8-1

Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis

2024-8-1

Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States

2024-8-1

Total cost of care of Medicare Advantage beneficiaries participating in an appointment-based model in a national pharmacy chain

2024-8-1

Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program

2024-8-1

The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B

2024-8-1

Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective

2024-7-27

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

2024-7-24

Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments

2024-7-22

Stakeholder perspectives on the sustainability of the United States biosimilars market

2024-7-16

Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them

2024-7-1

Affordability and adherence gains for Medicare Part D low-income subsidy recipients when low-income subsidy benefits expanded in 2024

2024-7-1

Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer

2024-7-1

Racial and social inequities in medication use: A review of articles responding to the <i>Journal of Managed Care</i> + <i>Specialty Pharmacy</i>’s Call to Action

2024-7-1

Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program

2024-7-1

Reducing disparities in medication use: Responding to managed care pharmacy’s imperatives

2024-7-1

Editor’s Note

2024-7-1

Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy

2024-7-1

Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States

2024-7-1

Clinical and economic evaluation of tralokinumab for atopic dermatitis

2024-7-1

Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study

2024-7-1

Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program

2024-7-1

Clinical characteristics and treatment patterns of patients with <i>NTRK</i> fusion–positive solid tumors: A multisite cohort study at US academic cancer centers

2024-7-1

Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative

2024-7-1

Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B

2024-6-26

Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives

2024-6-21

Impact of a tubeless, disposable insulin pump on emergency department visits and inpatient admissions among a Medicare population

2024-6-17

Cost burden of cirrhosis and liver disease progression in metabolic dysfunction–associated steatohepatitis: A US cohort study

2024-6-7